CA-XSOLLA
22.8.2024 10:01:27 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, proudly extends its strategic partnership with GameAnalytics, the leading analytics service for game developers and publishers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240822075172/en/
(Graphic: Xsolla)
The partnership marks a significant expansion of Xsolla's capabilities. By integrating GameAnalytics directly into the Xsolla Backend Solution, developers can access powerful analytics and monetization tools in one seamless interface. This integration redefines how developers approach game analytics and monetization, providing a comprehensive toolkit to enhance their understanding of player behavior, optimize revenue streams, and drive better business outcomes. Developers can now track critical metrics such as conversion rates, player retention, and lifetime value while leveraging Xsolla’s extensive payment processing capabilities, offering a unique advantage by combining data-driven insights and robust monetization tools under a single umbrella.
Jean-Philippe Steinmetz, Head of Xsolla Backend, highlights the strategic importance of expanding the partnership: “By incorporating GameAnalytics into Xsolla Backend, we are enhancing our platform's ability to deliver comprehensive game analytics and benchmarking. This collaboration allows us to provide developers with a deeper understanding of their games' performance, enabling them to make informed decisions that drive success.”
GameAnalytics, known for serving over 12,000 game studios and offering insights on more than 2.3 billion players each month, brings unparalleled expertise in analytics to this partnership. The integration with Xsolla Backend allows developers to access these insights effortlessly, providing a clear view of how their games perform across various metrics. This partnership enhances the analytic capabilities available to developers and simplifies integrating these insights with monetization strategies, ultimately helping developers maximize their revenue potential.
Allison Bilas, COO at GameAnalytics, expressed her enthusiasm for the expansion of the partnership: “We are excited to expand our relationship with Xsolla by integrating our analytics suite into Xsolla Backend. This integration allows us to deliver even more value to developers, helping them better understand their games and make data-driven decisions to enhance player experiences.”
The collaboration underscores Xsolla’s dedication to providing game developers with the tools they need to succeed in a competitive market. By combining the power and efficiency of Xsolla Backend with Xsolla's payment and monetization tools and GameAnalytics' industry-leading data analysis capabilities, developers now have access to a powerful, all-in-one solution that simplifies the process of building, tracking, and improving game performance.
For more information, please visit xsolla.pro/xbegameanalytics.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit xsolla.com
About GameAnalytics
GameAnalytics is the leading analytics solution for developers, game studios, and powerhouse publishers globally. Their network covers 100,000 games played by over 1.75 billion people for an average of 24 billion monthly sessions. The GameAnalytics platform enables game development teams to rapidly refine gameplay, improve retention, and increase revenue with real-time data analysis for all major game engines and operating systems through a simple SDK integration. GameAnalytics was founded in 2012 by Danish serial entrepreneur Morten E. Wulff, who remains the company's Chairman today. After raising over $8M in funding, the leading mobile advertising company, Mobvista, acquired the company in 2016. To learn more and get started for free, visit gameanalytics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822075172/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom